Business

Avera Health and Sema4 Announce Collaboration to Advance Precision Oncology Care

Building on its commitment to genomic research and healthcare innovations, Avera Health will utilize Sema4’s health intelligence platform to further advance

articleGenedx Holdings Corp.August 11, 20215/company/genedx-holdings-corp/news/avera-health-and-sema4-announce-collaboration-to-advance-precision-oncology-care-2021
Avera Health and Sema4 Announce Collaboration to Advance Precision Oncology Care

About this update from Genedx Holdings Corp.

[{"type":"text","content":"Building on its commitment to genomic research and healthcare innovations, Avera Health will utilize Sema4’s health intelligence platform to further advance cancer care\nSIOUX FALLS, S.D and STAMFORD, Conn., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Avera Health, an integrated regional health care system that serves 300 locations across the Upper Midwest, and Sema4, a patient-centered health intelligence company, today announced a new collaboration launching a precision medicine initiative. This initiative will initially focus on advancing oncology care, enabling Avera Health’s providers and patients to benefit from data-driven insights that inform targeted cancer treatments. Avera Cancer Institute has had a robust precision oncology program for several years in which the patient’s tumor has been genetically sequenced to guide individualized cancer treatment. This collaboration will take that a step further by leveraging Centrellis®, Sema4’s health intelligence platform, to curate, structure and integrate clinical and genomic data to support both cancer research and clinical care at Avera Health. Sema4 will deliver predictive disease network models and clinically actionable insights, empowering Avera Health’s providers to further improve the prevention, detection, and treatment of cancer for their patients. Sema4 will also offer digital tools, which give Avera Health’s providers the ability to readily search for cohorts of patients based on clinical criteria, view a patient’s treatment history that is contained in the curated data as an interactive timeline, and more systematically match patients to clinical trials. “Avera Health has a longstanding commitment to genomics and personalized medicine, and a forward- thinking approach to understand the critical role it plays in generating better health outcomes,” said John Lee, MD, FACS, Chief Medical Officer for Cancer Research at the Avera Cancer Institute. “Our collaboration with Sema4, and the resulting access to curated and structured real-time oncology data, will allow our providers to leverage cutting-edge tools that will improve the delivery and quality of cancer care. This access to increasingly rich clinical data throughout the patient journey will also accelerate critical, lifesaving treatment options.” The collaboration between Avera Health and Sema4 significantly builds upon Ave...

More updates from Genedx Holdings Corp.